DECEMBER: NDI guidance comments and DMAA
The day of reckoning over the FDA's draft guidance on new dietary ingredients (NDIs) was Dec 2 (the deadline for filing formal comments). And the message from industry was loud and clear. Tear it up and start again.
But the trade also faced difficult questions over the use of the stimulant DMAA (1,3- dimethylamylamine) after the Dept of Defense pulled supplements containing it from all stores on military bases pending a safety probe and two more firms were hit with class action lawsuits challenging its legal status in supplements.
For a video summary of the NDI comments from Stephen Daniells, click here.
For a listing of all of our coverage of the NDI guidance, click here.
